Scholarlink

<p>Adult chronic nonbacterial osteitis (CNO) is a&#xa0;rare autoinflammatory bone disease formerly described under heterogeneous terms, such as SAPHO (acronym for synovitis, acne, pustulosis, hyperostosis and osteitis) or sternocostoclavicular hyperostosis (SCCH). New international consensus recommendations now define adult CNO as a&#xa0;distinct nosological entity with osteitis as the obligatory hallmark. The disease typically presents as monofocal inflammation of the anterior chest wall; cutaneous manifestations are not obligatory. Overlaps with axial spondylarthritis (axSpA) or psoriatic arthritis (PsA) are recognized but uncommon (&lt; 30% of cases). The diagnostics follow a&#xa0;structured algorithm involving clinical assessment, targeted laboratory diagnostics (including bone metabolism markers) and magnetic resonance imaging (MRI)-based imaging. Treatment decisions are based on the combined presence of clinical symptoms and radiological activity. A&#xa0;stepwise approach is recommended, starting with nonsteroidal anti-inflammatory drugs (NSAID), followed by intravenous bisphosphonates or tumor necrosis factor (TNF) alpha inhibitors in cases of insufficient response. Treatment monitoring should be carried out every 12&#xa0;weeks. In stable remission, tapering or withdrawal can be considered. All specific therapies are performed off-label and require formal reimbursement approval. The management should be rheumatologically led and interdisciplinary. Lifestyle modifications, such as smoking cessation, physical activity and dental care during bisphosphonate therapy, are integral components. The new recommendations enable a&#xa0;clinically applicable, standardized management of this insufficiently defined disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adulte chronische nichtbakterielle Osteitis

  • 期刊论文

  • 发表日期：

    2025年7月21日

查看全文
  • Philipp Klemm,
  • Pascal van Wijnen,
  • Gunter Assmann

摘要

Adult chronic nonbacterial osteitis (CNO) is a rare autoinflammatory bone disease formerly described under heterogeneous terms, such as SAPHO (acronym for synovitis, acne, pustulosis, hyperostosis and osteitis) or sternocostoclavicular hyperostosis (SCCH). New international consensus recommendations now define adult CNO as a distinct nosological entity with osteitis as the obligatory hallmark. The disease typically presents as monofocal inflammation of the anterior chest wall; cutaneous manifestations are not obligatory. Overlaps with axial spondylarthritis (axSpA) or psoriatic arthritis (PsA) are recognized but uncommon (< 30% of cases). The diagnostics follow a structured algorithm involving clinical assessment, targeted laboratory diagnostics (including bone metabolism markers) and magnetic resonance imaging (MRI)-based imaging. Treatment decisions are based on the combined presence of clinical symptoms and radiological activity. A stepwise approach is recommended, starting with nonsteroidal anti-inflammatory drugs (NSAID), followed by intravenous bisphosphonates or tumor necrosis factor (TNF) alpha inhibitors in cases of insufficient response. Treatment monitoring should be carried out every 12 weeks. In stable remission, tapering or withdrawal can be considered. All specific therapies are performed off-label and require formal reimbursement approval. The management should be rheumatologically led and interdisciplinary. Lifestyle modifications, such as smoking cessation, physical activity and dental care during bisphosphonate therapy, are integral components. The new recommendations enable a clinically applicable, standardized management of this insufficiently defined disease.